ATE181920T1 - Ueberbrückte und nicht-überbrückte heterocyclische spiroverbindungen - Google Patents

Ueberbrückte und nicht-überbrückte heterocyclische spiroverbindungen

Info

Publication number
ATE181920T1
ATE181920T1 AT91303135T AT91303135T ATE181920T1 AT E181920 T1 ATE181920 T1 AT E181920T1 AT 91303135 T AT91303135 T AT 91303135T AT 91303135 T AT91303135 T AT 91303135T AT E181920 T1 ATE181920 T1 AT E181920T1
Authority
AT
Austria
Prior art keywords
alkyl
alkoxy
bridged
amino
compounds
Prior art date
Application number
AT91303135T
Other languages
English (en)
Inventor
Abraham Fisher
Yoffi Segall
Ezra Shirin
Yishai Karton
Haim Meshulam
Original Assignee
Israel Inst Biolog Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/507,228 external-priority patent/US5053412A/en
Application filed by Israel Inst Biolog Res filed Critical Israel Inst Biolog Res
Application granted granted Critical
Publication of ATE181920T1 publication Critical patent/ATE181920T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT91303135T 1990-04-10 1991-04-09 Ueberbrückte und nicht-überbrückte heterocyclische spiroverbindungen ATE181920T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50770890A 1990-04-10 1990-04-10
US07/507,228 US5053412A (en) 1990-04-10 1990-04-10 Spiro nitrogen-bridged heterocyclic compounds
AU81241/91A AU636047B2 (en) 1990-04-10 1991-07-23 Spiro bridged and unbridged heterocyclic compounds

Publications (1)

Publication Number Publication Date
ATE181920T1 true ATE181920T1 (de) 1999-07-15

Family

ID=27156423

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91303135T ATE181920T1 (de) 1990-04-10 1991-04-09 Ueberbrückte und nicht-überbrückte heterocyclische spiroverbindungen

Country Status (8)

Country Link
EP (1) EP0452101B1 (de)
JP (1) JP3266624B2 (de)
AT (1) ATE181920T1 (de)
AU (1) AU636047B2 (de)
CA (1) CA2039826C (de)
DE (1) DE69131409T2 (de)
ES (1) ES2137926T3 (de)
IL (1) IL97726A (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
PT777671E (pt) * 1994-08-24 2000-08-31 Astrazeneca Ab Compostos espiro-azabiciclicos uteis em terapia
US7863291B2 (en) * 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US9034891B2 (en) 2009-01-26 2015-05-19 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
CA2750777C (en) * 2009-01-26 2018-04-03 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
US8278320B2 (en) 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
EP2493894B1 (de) 2009-10-28 2014-01-29 Bristol-Myers Squibb Company Ayabicyclische verbindungen als alpha-7-nikotin-acetylcholin-rezpetorliganden
AU2009354790A1 (en) * 2009-10-29 2012-06-14 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
CN101798311A (zh) * 2010-04-07 2010-08-11 天津炜杰凯华科技有限公司 顺式西维美林的制备方法
CN103025744A (zh) 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
EP2855471B1 (de) 2012-05-24 2017-11-15 Bristol-Myers Squibb Company Chinuclidin, 1-azabicyclo[2.2.1]heptan-, 1-azabicyclo[3.2.1]oktan- und 1-azabicyclo[3.2.2]nonan-verbindungen als nikotinische alpha-7-acetylcholin-rezpetorliganden
JP5714745B2 (ja) * 2014-04-28 2015-05-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ α７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物
AU2021270664B2 (en) * 2020-05-12 2024-05-30 Beijing Greatway Pharmaceutical Technology Co., Ltd. Compound for adjusting activity of NMDA receptor, and pharmaceutical composition and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629276A (en) * 1969-07-16 1971-12-21 Abbott Lab 2-amino-5-spiro-substituted-oxazo compounds
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
GB8808433D0 (en) * 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
GB8816299D0 (en) * 1988-07-08 1988-08-10 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
AU636047B2 (en) 1993-04-08
DE69131409D1 (de) 1999-08-12
IL97726A (en) 1994-12-29
EP0452101A3 (en) 1993-02-24
ES2137926T3 (es) 2000-01-01
JP3266624B2 (ja) 2002-03-18
EP0452101B1 (de) 1999-07-07
CA2039826C (en) 2002-01-15
DE69131409T2 (de) 2000-02-03
AU8124191A (en) 1993-01-28
JPH06293761A (ja) 1994-10-21
EP0452101A2 (de) 1991-10-16
CA2039826A1 (en) 1991-10-11

Similar Documents

Publication Publication Date Title
DE69131409D1 (de) Ueberbrückte und nicht-überbrückte heterocyclische Spiroverbindungen
ES2059069T3 (es) Nuevos derivados de 1-alcoxi-(2-acilamino-etil)-naftalenos y su procedimiento de preparacion.
BG105271A (bg) Производни на 1h-имидазопиридин
ATE283268T1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
ATE143943T1 (de) Arylglycinamidderivate, verfahren zur deren herstellung und deren verwendung zur therapie der dysurie
ES2094204T3 (es) Derivados de piperazina.
ATE108448T1 (de) Piperdinyloxy- und chinindidinyloxy- isoxazol- derivate, ihre herstellung und ihre therapeutische verwendung.
DE69018726D1 (de) Cumarinderivate, ihre Herstellung und ihre Verwendung zur Behandlung von zerebrovaskulären Störungen.
NO174712C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive heterocykliske forbindelser
ES2088903T3 (es) Nuevos inhibidores de la s-adenosilmetionina descarboxilasa.
FI103970B1 (fi) Menetelmä kivun lievittämiseen sekä ihotautien ja muistin toimintahäiriöiden hoitoon tarkoitettujen 3-(1,2-bentsisoksatsol-3-yyli)-4-pyridiiniamiinien ja näiden johdannaisten valmistamiseksi
NO150436C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-fenylamino-imidazolin-derivater
FI900231A0 (fi) Cyklohexanacetaminderivat.
ATE47851T1 (de) 1,5-benzoxathiepin-derivate, deren herstellung und verwendung.
SE8901060D0 (sv) New compounds
ATE10370T1 (de) Benzothiazinderivate, verfahren zu ihrer herstellung und ihre verwendung.
DE69119642D1 (de) Verwendung von Pyrido-Indol-Derivaten bei der Behandlung ischämischer Störungen
NO830399L (no) Fremgangsmaate ved fremstilling av nye carbacycliner
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
ATE19881T1 (de) Tropyl- und pseudotropylalkylbenzoate und ihre verwendung in der behandlung von migraene.
FR2566407B1 (fr) Nouveaux derives de l'isoxazoloquinoleine, procede de preparation, application a titre de medicaments, et compositions les renfermant
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
ATE108444T1 (de) 3-isoxazolonderivate, ihre herstellung und ihre anwendung in der therapeutik.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee